Skip to main content
CLDX
NASDAQ Life Sciences

巴索维单抗复治显示出在冷性荨麻疹和SD中具有深远的疗效，强化了其最佳治疗方案的特征

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$28.673
Mkt Cap
$2.003B
52W Low
$14.4
52W High
$31.31
Market data snapshot near publication time

summarizeSummary

Celldex Therapeutics 在2026年AAAAI会议上展示了其主要资产巴索维单抗的新正相Phase 2数据，证明了在冷性荨麻疹（ColdU）和症状性皮肤划痕症（SD）患者中的复治取得了与初次治疗相似的深远疗效。具体来说，62%的冷性荨麻疹患者和60%的SD患者在开放标签扩展试验的第20周取得了完全响应，且该比例与初次治疗率一致。这些数据很重要，因为它们强化了巴索维单抗作为'第一和最佳治疗方案'的潜力，通过展示复治后的持久疗效，这对于慢性疾病至关重要。这种积极的更新进一步降低了正在进行的全球第三期试验的风险，该试验于2025年末启动，用于评估巴索维单抗在冷性荨麻疹和SD中的疗效，并提高了该药物的长期商业前景。投资者现在将密切关注这一关键第三期研究的进展和最终结果。

在该公告发布时，CLDX的交易价格为$28.67，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20亿。 52周交易区间为$14.40至$31.31。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article